MARKET

CUE

CUE

Cue Biopharma Inc
NASDAQ
29.26
-2.06
-6.58%
After Hours: 30.00 +0.74 +2.53% 19:04 05/12 EDT
OPEN
30.76
PREV CLOSE
31.32
HIGH
33.59
LOW
28.10
VOLUME
157.81K
TURNOVER
--
52 WEEK HIGH
41.42
52 WEEK LOW
4.971
MARKET CAP
95.25M
P/E (TTM)
-3.4729
1D
5D
1M
3M
1Y
5Y
1D
Watching Cue Biopharma; Fugazi Research Issues Report On Co. Titled "$CUE: Reverse Splits, PIPE Dilution, and the Illusion of Recovery"
Benzinga · 1d ago
Weekly Report: what happened at CUE last week (0504-0508)?
Weekly Report · 1d ago
Cue Biopharma grants CEO stock options for 655,074 shares at $30.42 each
PUBT · 5d ago
CUE BIOPHARMA REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 5d ago
Cue Biopharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Barchart · 5d ago
Cue Biopharma trading resumes
TipRanks · 05/04 17:37
Cue Biopharma trading halted, volatility trading pause
TipRanks · 05/04 17:31
NASDAQ TRADE HALT <CUE.O> VOLATILITY TRADING PAUSE AT 01:27 PM
Reuters · 05/04 17:27
More
About CUE
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body. Its proprietary platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body’s intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation. Its lead programs include drug product candidates designed to: CUE-400 series (Autoimmune Diseases) enhance regulatory T cells (Tregs) with a novel mechanism to proliferate, generate Tregs, and restore immune balance (CUE-401 for autoimmune conditions);CUE-500 series (Targeted Cell Depletion) redirect antiviral T cells to target eliminate pathogenic cells (CUE-501 for autoimmune B cell depletion); and CUE-100 series (Oncology) selectively activate tumor-specific T cells.

Webull offers Cue Biopharma Inc stock information, including NASDAQ: CUE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CUE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CUE stock methods without spending real money on the virtual paper trading platform.